← Leaderboards
Christian Harding
Vaxnewmo, Llc
$10,084,816
Attributed
$10,084,816
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,084,816 · 5
By mechanism
R44$6,900,317 · 3
R42$2,591,387 · 1
R41$593,112 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseEscherichia ColiPolysaccharidesEnzymesCarrier ProteinsProductionVaccine ProductionVaccinesTechnologySerotypingImmunogenicityFormulationAntibody ResponseConjugate VaccinesPreventGlycosylationVaccine DevelopmentComplexLifeBacterial PolysaccharidesLinkCessation Of LifeInfectionPathogenic Bacteria
Grant awards (13)
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections$1,000,000
R44 · FY2025 · AI · contact PI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$999,717
R42 · FY2025 · AI · contact PI
Development of a Group B Streptococcus bioconjugate vaccine$995,682
R44 · FY2025 · AI · contact PI
Development of a Group B Streptococcus bioconjugate vaccine$995,682
R44 · FY2024 · AI · contact PI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$994,178
R42 · FY2024 · AI · contact PI
Development of a Group B Streptococcus bioconjugate vaccine$1,000,000
R44 · FY2023 · AI · contact PI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$298,254
R42 · FY2023 · AI · contact PI
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections$293,112
R41 · FY2023 · AI · contact PI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$984,934
R44 · FY2022 · AI · contact PI
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections$300,000
R41 · FY2022 · AI · contact PI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$299,238
R42 · FY2022 · AI · contact PI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$992,959
R44 · FY2021 · AI · contact PI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$931,060
R44 · FY2020 · AI · contact PI